A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries

Burns Clinical Trial

Official title:

A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01138917
• Other study ID #: CTP001-5
• Status: Completed
• Phase: N/A
• Start date: May 21, 2010
• Est. completion date: August 26, 2015

Study information

• Verified date: May 2019
• Source: Avita Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, within-patient controlled study to compare the clinical performance of the ReCell Device with that of Split-thickness Meshed Skin Grafts for the treatment of second degree burns. The hypothesis to be supported are: 1) non-inferiority with the primary efficacy endpoint defined as recipient site wound closure at week 4 follow-up visit of the ReCell-treated area as compared to that of the STMSG-treated area, and 2)superiority in the healing of the ReCell donor site as compared to the STMSG donor site at week 1.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 101
• Est. completion date: August 26, 2015
• Est. primary completion date: August 29, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• The subject requires primary skin grafting as a result of an acute thermal burn injury

• The area of the burn injury is at least 200cm2 (1% TBSA in adults) if a contiguous wound, or at least 100cm2 for each of 2 noon-contiguous wounds

• The area of total burn injury is 1-20% TBSA

• The burn injured area can be divided into two treatment areas ( control and treatment) with 100-320cm2 area for each treatment type

• The study treatment area is a second degree burn injury

• The subject is between 18-65 years of age

• The subject is willing to complete all follow-up evaluations required by the study protocol

• The subject is to abstain from any other treatment of the wound(s) for the duration of the study unless medically necessary

• The subject agrees to abstain from enrollment in any other clinical trial for the duration of the study

• The subject and/or guardian are able to read and understand instructions and give informed, voluntary, written consent

• The subject is able and willing to follow the protocol requirements

Exclusion Criteria:

• The subject's burn injuries were caused by chemicals, electricity, and/or radioactive substances

• The total subject burn injury is less than 1% or more than 20% TBSA

• The subject has a microbiologically proven pre-existing local or systemic bacterial infection

• The subject has been receiving a systemic antibiotic for more than 48 hours prior to grafting

• The subject is known to have a pre-existing condition that may interfere with wound healing ( e.g. malignancy, diabetes, or autoimmune disease)

• The subject is unable to follow the protocol

• The subject is taking medication known to have an effect on wound healing or skin pigmentation ( e.g. systemic corticosteroids, retinoids, etc)

• The subject has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives

• The subject has a known hypersensitivity to Trypsin or Compound sodium Lactate for Irrigation (Hartmann's) solution

Related Conditions & MeSH terms

• Burns

Intervention

Device:
• ReCell and Split-thickness skin graft
The surgeon will be required to select two similar non-contiguous injury areas with both areas being at least 100cm2 and second degree depth/severity. One area will be treated using ReCell and the second using Split-thickness Skin Graft.

Locations

Country	Name	City	State
United States	NC Jaycee Burn Center at University of NC at Chapel Hill	Chapel Hill	North Carolina
United States	USAISR	Fort Sam Houston	Texas
United States	Shands Burn Center at University of Florida	Gainesville	Florida
United States	Indiana University - Richard M. Fairbanks Burn Center at Wishard Memorial Hospital	Indianapolis	Indiana
United States	Texas Tech University Health Sciences Center	Lubbock	Texas
United States	University of Tennessee Medical Center	Memphis	Tennessee
United States	Arizona Burn Center at Maricopa Integrated Health Systems	Phoenix	Arizona
United States	Virginia Commonwealth University Health System- Evans Haynes Burn Center	Richmond	Virginia
United States	University of California Davis Regional Burn Center	Sacramento	California
United States	Tampa General Hospital	Tampa	Florida
United States	The Burn Center at Washington Hospital Center	Washington	District of Columbia
United States	Wake Forest University Health Sciences	Winston-Salem	North Carolina

Sponsors (5)

Lead Sponsor	Collaborator
Avita Medical	BioStat International, Inc., MedDRA Assistance Inc, Royal Perth Hospital, United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of RECELL-treated Area Closure Compared to Control at 4 Weeks (Non-inferiority)	Recipient site wound closure for both ReCell and STMSG will be defined as the presence of >=95% epithelialization with contiguous layer of viable epithelium without the need for secondary surgical intervention. Factors considered during the assessment included color, presence of granulation tissue, and whether or not the entire wound is covered with a contiguous layer of viable epithelium. Using this definition, some small degree of punctate blistering was acceptable as long as the wound was >=95% epithelialized.	4 weeks
Primary	Incidence of RECELL Donor Site Healing Compared to Control at 1 Week (Superiority)	Donor site healing will be considered as complete (100%) wound closure if the following criteria were met: an ability to separate the dressing from the wound bed with visible presence over the entirety of the wound of dry, opalescent-pink external surface representing the newly formed outer cornfield layer of the epidermis.	1 week
Secondary	Percent of Epithelialization at Each Visit Through Week 16	The percent epithelialization of the RECELL and Control treated sites will be assessed using standardized planimetry/tracing procedures. The tracings were uploaded to a Central Reading Facility for calculation of percent epithelialization using a computerized measurement technique.	Each visit through Week 16
Secondary	Wound Closure at Week 2 (Based on Investigators Assessment)	The proportion of recipient sites achieving wound closure at Week 2 was evaluated using the Investigators assessment of wound healing.	Week 2
Secondary	Mean Pain and Appearance Scores at RECELL and Control Recipient Sites (Subject Assessment)	Subject assessment of pain at the RECELL and Control recipient sites was performed at all study follow-up visits up to Week 16.; Subjects also assessed the satisfaction with the appearance of the treatment sites at the Week 16, 24, and 52 study follow-up visits. The subject assessments were performed using VAS (visual analogue scale) style questionnaires.; Pain VAS 0-100 where 0=non-existent pain and 100=severe pain. Appearance VAS 0-100 where 0=terrible and 100=exceptional	Pain (Weeks 1-16) and Appearance (Weeks 16-52)
Secondary	Mean Pain and Appearance Scores at Donor Sites (Subject Assessment)	Subject assessment of pain at the RECELL and Control donor sites was performed at all study follow-up visits up to Week 16.; Subjects also assessed the satisfaction with the appearance of the donor sites at the Week 16, 24, and 52 study follow-up visits. The subject assessments were performed using VAS (visual analogue scale) style questionnaires.; Pain VAS 0-100 where 0=non-existent pain and 100=severe pain. Appearance VAS 0-100 where 0=terrible and 100=exceptional.	Pain (Weeks 1-16) and Appearance (Weeks 16-52)